Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

17.2K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
17.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Author Correction: Magnon confinement in epitaxial antiferromagnetic oxide heterostructures.

Nature materials·2026
Same author

Magnon confinement in epitaxial antiferromagnetic oxide heterostructures.

Nature materials·2026
Same author

Association between dietary diversity and risk of depressive symptoms in Chinese children, adolescents, and college students.

Frontiers in nutrition·2026
Same author

Night-eating syndrome is associated with food consumption frequency among Chinese college students.

Scientific reports·2026
Same author

Toward Atomic-Scale Control over Structural Modulations in Quasi-1D Chalcogenides for Colossal Optical Anisotropy.

ACS nano·2025
Same journal

Whole-cell particle-based digital twin simulations from 4D lattice light-sheet microscopy data.

Cell·2026
Same journal

Systematic discovery of pathogen effector functions across human pathogens and pathways.

Cell·2026
Same journal

Structural basis for host membrane binding and remodeling by invading malaria parasites.

Cell·2026
Same journal

Multiscale integration of tissue and chromatin context converts cell heterogeneity into stable intestinal patterning.

Cell·2026
Same journal

Arc mediates intercellular tau transmission via extracellular vesicles.

Cell·2026
Same journal

Electromagnetic field-inducible in vivo gene switch for remote spatiotemporal control of gene expression.

Cell·2026
See all related articles

Related Experiment Video

Updated: Mar 25, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.3K

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

Boyang Zhao1, Joseph C Sedlak2, Raja Srinivas3

  • 1Computational and Systems Biology Program, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Cell
|March 1, 2016
PubMed
Summary
This summary is machine-generated.

Cancer treatment can exploit tumor vulnerabilities that emerge during drug resistance evolution. This study identifies "temporal collateral sensitivity" to new drugs in leukemia, extending survival in mice.

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

6.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Related Experiment Videos

Last Updated: Mar 25, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.3K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

6.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Area of Science:

  • Oncology
  • Cancer Evolution
  • Pharmacology

Background:

  • Current cancer therapy often treats drug resistance after relapse.
  • Tumor clonal evolution and associated fitness costs may create exploitable vulnerabilities.
  • This study introduces the concept of "temporal collateral sensitivity."

Purpose of the Study:

  • To investigate temporal collateral sensitivity in cancer drug resistance.
  • To explore vulnerabilities arising during the evolution of resistance to BCR-ABL1 inhibitors.
  • To identify novel therapeutic strategies targeting dynamic tumor vulnerabilities.

Main Methods:

  • Utilized a murine model of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL).
  • Employed a combined pharmacological screen and drug resistance selection approach.
  • Integrated genotypic, phenotypic, signaling, and binding measurements with computational modeling.

Main Results:

  • Discovered temporal and persistent collateral sensitivity to non-classical BCR-ABL1 drugs in resistant Ph(+) ALL subpopulations.
  • Demonstrated significant overall survival extension in treated mice.
  • Identified the sensitization mechanisms through comprehensive analyses.

Conclusions:

  • Temporal collateral sensitivity represents a promising therapeutic vulnerability in evolving cancers.
  • Focusing on evolutionary trajectories and drug pharmacological profiles can reveal new treatment strategies.
  • This approach holds potential for treating dynamic tumor vulnerabilities in hematological malignancies.